|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-6-9
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-10403642,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-14676113,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-14768038,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15023407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15591121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15749921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15781662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15870713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-15883172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-16491401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-16675576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-16729333,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-17046096,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-17060934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18310500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18316569,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18474013,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18477802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18485901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18821591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-18980227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-19018262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-19095497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-19190114,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-19201656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20478057-20139774
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
209
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20478057-Aged,
pubmed-meshheading:20478057-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20478057-Cancer Vaccines,
pubmed-meshheading:20478057-Carcinoma, Hepatocellular,
pubmed-meshheading:20478057-Chemotherapy, Adjuvant,
pubmed-meshheading:20478057-Cyclophosphamide,
pubmed-meshheading:20478057-Disease-Free Survival,
pubmed-meshheading:20478057-Europe,
pubmed-meshheading:20478057-Female,
pubmed-meshheading:20478057-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:20478057-Humans,
pubmed-meshheading:20478057-Infusions, Intravenous,
pubmed-meshheading:20478057-Injections, Intradermal,
pubmed-meshheading:20478057-Kaplan-Meier Estimate,
pubmed-meshheading:20478057-Liver Neoplasms,
pubmed-meshheading:20478057-Male,
pubmed-meshheading:20478057-Middle Aged,
pubmed-meshheading:20478057-Peptide Fragments,
pubmed-meshheading:20478057-T-Lymphocytes, Regulatory,
pubmed-meshheading:20478057-Telomerase,
pubmed-meshheading:20478057-Time Factors,
pubmed-meshheading:20478057-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Gastroenterology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany. tim.greten@nih.gov
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
